Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

被引：67

作者：

Livermore, DM ^{[1
]}

机构：

[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England

来源：

关键词：

D O I：

10.1093/jac/46.3.347

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

[No abstract available]

引用

页码：347 / 350

页数：4

共 26 条

[1] BAGER F, 1999, DANMAP 98 CONSUMPTIO
[2] BIRMINGHAM MC, 1999, 37 ANN M INF DIS SOC, P62
[3] BIRMINGHAM MC, 1999, 39 INT C ANT AG CHEM, P724
[4] A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
Blondeau, JM
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 : 1 - 11
[5] Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods
Boswell, FJ
Sunderland, J
Andrews, JM
Wise, R
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 : 29 - 32
[6] BUCHANAN L, 1999, 37 ANN M INF DIS SOC, P52
[7] Inhibition of protein synthesis by streptogramins and related antibiotics
Cocito, C
DiGiambattista, M
Nyssen, E
Vannuffel, P
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 : 7 - 13
[8] *CUB PHARM INC, 1999, DAPT BACKGR
[9] Dresser LD, 1998, PHARMACOTHERAPY, V18, P456
[10] FAGON JY, 1997, 20 INT C CHEM ICC SY, P44